Response to Comment on Monnier et al. Magnitude of the Dawn Phenomenon and Its Impact on the Overall Glucose Exposure in Type 2 Diabetes: Is This of Concern? Diabetes Care 2013;36:4057–4062

The dawn phenomenon in type 2 diabetes: How to assess it in clinical practice?

“…DPP-4 inhibitors were categorized along with sulphonylureas and glinides because these drugs are all insulinotropic agents, although the mechanism of action of DPP-4 inhibitors is much broader than its effects on insulin secretion alone [10]. This categorization has previously been used [4] and justified in a letter [11] in response to a question raised by Carr et al [12]. In addition, no differences were observed between glycaemic profiles in the two main groups selected by categories of treatment (insulin sensitizers alone, and either insulin secretagogues/insulin enhancers alone or in combination with insulin sensitizers).…”